Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Sep 17, 2018	CareDx broadens HeartCare availability Launches HeartCare registry to increase patient access to comprehensive surveillance solution of AlloMap and AlloSure Heart BRISBANE, Calif. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development, and	View HTML
Toggle Summary Aug 15, 2018	CareDx to Participate in Upcoming Investor Conference BRISBANE, Calif. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Peter Maag ,	View HTML
Toggle Summary Aug 09, 2018	CareDx Reports Second Quarter Results AlloSure launch momentum drives 48% revenue growth BRISBANE, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML
Toggle Summary Jul 16, 2018	CareDx to Announce Second Quarter 2018 Financial Results on August 9, 2018 BRISBANE, Calif. , July 16, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release	View HTML
Toggle Summary Jun 28, 2018	Flatiron Health CMO/CSO Joins CareDx Board of Directors Amy Abernethy adds clinical expertise and patient data insights to the CareDx Board BRISBANE, Calif. , June 28, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Jun 19, 2018	CareDx set to join Russell 2000, Russell 3000 and Russell Microcap Indexes BRISBANE, Calif. , June 19, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced today that it is set to join	View HTML
Toggle Summary Jun 05, 2018	CareDx Promotes Living Donor Transplantation Through Employee Policy The progressive CareDx Living Donor Employee Recovery Policy announced at ATC BRISBANE, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Jun 01, 2018	Key CareDx Events Scheduled at American Transplant Congress 2018 CareDx will have a strong presence at ATC, all major US transplant centers will be in attendance BRISBANE, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated,	View HTML
Toggle Summary May 24, 2018	CareDx to Hold Press Conference at American Transplant Congress BRISBANE, Calif. , May 24, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will hold a press conference* at 4:00	View HTML
Toggle Summary May 10, 2018	CareDx Reports First Quarter Results AlloSure launch momentum drives 21% revenue growth Further expands product offerings for transplant patients BRISBANE, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically	View HTML